TScan Therapeutics, Inc. — Form 8-K
Filed September 11, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Form 8-K filed 2026-09-11 reports Item 5.02 disclosure regarding departure of directors or certain officers and compensatory arrangements of certain officers, effective 2026-09-08. The filing document references exist but specific names, amounts, dates, and terms are not detailed in the header text provided; full details would require reading the complete 8-K document.
Why this rating
Officer/director changes are routine for TScan's $57M market cap; no specific compensation amounts, severance terms, or strategic impact quantified in available text. Standard governance disclosure.
Extracted items
See more from September 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.